Welcome to our dedicated page for Halozyme Thrp SEC filings (Ticker: HALO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing Halozyme鈥檚 royalty-rich disclosures can feel like searching for a single amino acid in a protein chain. The company鈥檚 300-page reports weave ENHANZE licensing revenue, clinical trial spend, and complex milestone accounting into dense tables that few investors have time to unravel. If you have ever typed 鈥淗alozyme insider trading Form 4 transactions鈥� or 鈥淗alozyme quarterly earnings report 10-Q filing鈥� into a search bar, you already know the challenge.
Stock Titan solves the problem in minutes, not days. Our AI reads every 10-K, 10-Q, 8-K and S-3 the instant it hits EDGAR, then delivers plain-English answers to common questions such as 鈥淗alozyme SEC filings explained simply鈥� and 鈥渦nderstanding Halozyme SEC documents with AI.鈥� Need to monitor material events? 鈥淗alozyme 8-K material events explained鈥� appears with context minutes after filing. Want alerts on executive activity? 鈥淗alozyme Form 4 insider transactions real-time鈥� and 鈥淗alozyme executive stock transactions Form 4鈥� land in your dashboard before the market can react.
Each document is paired with concise AI summaries that spotlight: royalty percentages from Roche or Pfizer collaborations, pipeline milestone triggers, and cash-flow impacts of inventory builds. Use cases include:
- Comparing R&D burn across quarters with our 鈥淗alozyme earnings report filing analysis.鈥�
- Reviewing compensation tables via 鈥淗alozyme proxy statement executive compensation.鈥�
- Scanning the 鈥淗alozyme annual report 10-K simplified鈥� section for segment revenue trends.
Whether you are modeling future royalties or timing trades around clinical catalysts, our real-time updates and expert insights transform raw HALO disclosures into decision-ready intelligence鈥攏o PhD in biochemistry required.
Helen Torley, President and CEO and a director of Halozyme Therapeutics (HALO), exercised a total of 60,000 stock options at an $8.11 exercise price and concurrently sold the resulting 60,000 common shares over three days. The sales were executed at weighted-average prices reported in ranges between $62.54 and $64.96 per share, and the Form reports 733,719 shares beneficially owned by the reporting person following these transactions.
The filings state the transactions were made under a written Rule 10b5-1 trading plan adopted March 21, 2025, and that the sold shares were acquired upon exercise of options with ten-year terms expiring in February 2026. The underlying options were originally granted February 3, 2016, with a four-year vesting schedule.
Halozyme Therapeutics (HALO) President and CEO Helen Torley executed a series of pre-planned transactions under a Rule 10b5-1 trading plan established on March 21, 2025. The transactions occurred over three consecutive days:
- June 20, 2025: Exercised 20,000 options at $8.11 and sold 20,000 shares at avg. $52.96
- June 23, 2025: Exercised 20,000 options at $8.11 and sold 20,000 shares at avg. $52.57
- June 24, 2025: Exercised 20,000 options at $8.11 and sold 20,000 shares (4,489 at avg. $53.11 and 15,511 at avg. $53.91)
Following these transactions, Torley holds 733,719 shares directly and 316,569 options at $8.11 strike price expiring February 3, 2026. The options were originally granted in 2016 with a 4-year vesting schedule. All transactions were executed under a pre-established 10b5-1 trading plan, demonstrating compliance with insider trading regulations.
FAQ
What is the current stock price of Halozyme Thrp (HALO)?
What is the market cap of Halozyme Thrp (HALO)?
